ClinicalTrials.gg
CompletedNCT00555880Updated Jun 14, 2021Results posted

Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension

A Phase 4 interventional study of Midodrine hydrochloride and Placebo in Hypotension, Orthostatic, sponsored by Shire. Completed at 11 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Sep 2004, registered Nov 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing midodrine in Hypotension, Orthostatic — none open to participants now, none under way, none of them phase 3. Midodrine · Hypotension, Orthostatic.

Enrollment
11th of 16
24 · median 42
Started
2004
the only one that year
Phase 4
6 of 16
none open now
Registered
6th of 16
by date
Lead sponsor
5 of 16
Shire

Among the 16 studies testing midodrine in Hypotension, Orthostatic, this one is the 11th largest by enrollment, is the only one that started in 2004, is one of 6 in phase 4, and was the 6th registered.

Hypotension, Orthostatic

159 studies on the registry are indexed under Hypotension, Orthostatic; 35 are open to participants now.

Browse Hypotension, Orthostatic studies →

Open to participants now

None of the 16 studies testing midodrine in Hypotension, Orthostatic is open now. The open studies under Hypotension, Orthostatic, anywhere →

About midodrine

Midodrine: first FDA approval 1996 (PROAMATINE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 23 Hypotension, Orthostatic studies recruiting now, 8 (35%) set no upper age limit and 8 (35%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing midodrine in Hypotension, Orthostatic as a file.
02

Study summary

The purpose of this clinical study is to evaluate the clinical effect of midodrine hydrochloride (ProAmatine®) compared to placebo in patients with orthostatic hypotension by measuring the time to onset of near syncopal symptoms and assessing several cardiovascular measurements, such as heart rate, blood pressure, and ECG, using the tilt table test.

03

Conditions studied

  • Hypotension, Orthostatic
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The male or female subjects must be 18 years of age or older and ambulatory. (Subjects must not require assistance with a walker or wheelchair to perform regular daily activities at all times.)
  • Women of must have a negative serum beta HCG pregnancy test at screening and baseline.
  • The subject has been diagnosed with symptomatic orthostatic hypotension due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathy (i.e. neurogenic orthostatic hypotension).
  • The subject manifests one of the following symptoms while standing or has a history of one of the following when not treated for orthostatic hypotension: dizziness, lightheadedness, feeling faint or feeling like they may black out.
  • The subject is willing and able to undergo the procedures required by this protocol including morning office visits, assessment completion, protocol compliance and participation in the .
  • The subject has signed an Institutional-Review-Board approved written form prior to any study procedures taking place.

Exclusion criteria

Exclusion Criteria:

  • The subject is a pregnant or lactating female.
  • The subject has pre-existing sustained supine hypertension greater than 180 mm Hg systolic and 110 mm Hg diastolic.
  • The subject is taking medications such as vasodilators, pressors, diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, combined alpha and beta-blockers, MAOI's, herbals or specific mixed effect medications.
  • The Principal Investigator deems any laboratory test abnormality clinical significant.
  • The subject has a diagnosis of any of the following disorders at the time of screening: pheochromocytoma; cardiac conditions including: congestive heart failure within the previous 6 months, myocardial infarction within the previous 6 months, symptomatic coronary artery disease, history of ventricular tachycardia, or uncontrolled cardiac arrhythmias; thyrotoxicosis; uncontrolled diabetes mellitus (uncontrolled defined as a HgbA1c greater than or equal to 10%); history of cerebrovascular accident, (TIA) or symptomatic carotid artery stenosis within the previous 6 months; history of coagulopathies; pulmonary hypertension; severe psychiatric disorders; renal failure (Creatinine equal to or greater than 2 times the )
  • The subject has a concurrent chronic or acute illness, disability, or other condition that might confound the results of the tests and/or measurements administered in this trial, or that might increase the risk to the subject.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1

    Drug: Midodrine hydrochloride

  • Placebo comparator
    2

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Onset of Near-syncopal Symptoms During Tilt Table Testing

    The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: 1 hour post-dose

  2. Time to Onset of Near-syncopal Symptoms During Tilt Table Testing Analysis #2

    The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near- syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out. In this outcome measure, the data analyzed are the same as for Outcome Measure 1 but the summary data are presented as least squares mean (standard error).

    Time frame: 1 hour post-dose

  3. Time to Onset of Near-syncopal Symptoms During Tilt Table Testing-Re-analysis With The Koch Procedure

    The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out. The Koch procedure is a 3-step process to analyze results while utilizing the available information on magnitude of differences.

    Time frame: 1 hour post-dose

Secondary outcomes

  1. Time to Onset of Near-syncopal Symptoms in The Per-protocol Population

    The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: 1 hour post-dose

  2. Time to Onset of Near-syncopal Symptoms in The Per-protocol Population Analysis #2

    The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near- syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out. In this outcome measure, the data analyzed are the same as for Outcome Measure 4 but the summary data are presented as least squares mean (standard error).

    Time frame: 1 hour post-dose

  3. Time to Near-syncopal Symptoms at Treatment Visit 1

    The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: 1 hour post-dose

  4. Duration of The Effect of Treatment at 3 Hours Post-dose

    Duration of effect was defined as the difference in time to onset of near-syncopal symptoms between the first and second tilt table test, conducted at 1 hour and 3 hours post-dose, respectively, at Treatment Visit 2 (time to onset at 3 hours minus time at 1 hour). The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: 1 and 3 hours post-dose

  5. Total Score of the Orthostatic Hypotension Symptom Assessment (OHSA)

    The OHSA measures the severity of six symptoms/symptom complexes associated with orthostatic hypotension. Subjects rated symptoms experienced during the tilt table test on an eleven-point scale from "none" to "worst possible". The OHSA total score is the sum of six subscales, ranging from 0 (no symptoms) to 60 (worst possible symptoms). The OHSA was completed after the tilt table test was over, but was answered with reference to symptoms experienced during testing. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: Approximately 1 hour post-dose

  6. Scores for 6 Items of The OHSA

    The OHSA measures the severity of six symptoms/symptom complexes associated with OH: dizziness, lightheadedness, and feeling faint; problems with vision; weakness; fatigue; trouble concentrating; and head/neck discomfort. Subjects rated symptoms experienced during the tilt table test on an eleven-point scale from "none" to "worst possible". Scores for each subscale range from 0 (no symptoms) to 10 (worst possible symptoms). The OHSA was completed after the tilt table test was over, but was answered with reference to symptoms experienced during testing. The tilt table test is a 10-minute assessment performed using a tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured with straps to prevent injury. After an equilibration period with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, and feeling faint.

    Time frame: Approximately 1 hour post-dose

  7. Number of Participants With Improvement of Clinician Clinician's Global Impression- Improvement (CGI-I) Scores After Tilt Table Test

    The CGI-I instrument assesses the overall impression of the subject's orthostatic hypotension during the tilt table test by using a 7-point scale, with 1 being Very much improved; 2, Much improved; 3, Slightly improved; 4, No change; 5, Slightly worse; 6, Much worse; and 7, Very much worse. The clinician completed the CGI-I after each of the tilt table tests. A patient was assessed as "Improved" if the score was 1, 2, or 3. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: 1 and 3 hours post-dose

  8. Number of Participants With Improvement of Patient CGI-I Scores After Tilt Table Test

    The CGI-I instrument assesses the overall impression of the subject's orthostatic hypotension during the tilt table test by using a 7-point scale, with 1 being Very much improved; 2, Much improved; 3, Slightly improved; 4, No change; 5, Slightly worse; 6, Much worse; and 7, Very much worse. The patient completed the CGI-I after each of the tilt table tests. A patient was assessed as "Improved" if the score was 1, 2, or 3. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: 1 and 3 hours post-dose

  9. Final Blood Pressure During Tilt Table Testing

    Blood pressure was recorded just before tilt table testing and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: 1 hour post-dose

  10. Systolic Blood Pressure at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2

    Blood pressure was recorded just before tilt table testing, at each minute during tilt table testing, and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: 1 and 3 hours post-dose

  11. Diastolic Blood Pressure at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2

    Blood pressure was recorded just before tilt table testing, at each minute during tilt table testing, and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: 1 and 3 hours post-dose

  12. Heart Rate at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2

    Heart rate was recorded just before tilt table testing, at each minute during tilt table testing, and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

    Time frame: 1 and 3 hours post-dose

  13. Number of Participants With Shifts in Reference to Normal Range For Hematology Analytes at Discharge

    For hematology, blood samples (5.0mL) were taken at screening, study admission (if greater than 14 days since screening) and discharge/early termination. The following parameters were assessed: hemoglobin, hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cell count - total and differential (WBC), and platelet count. A shift in reference to normal was either lower or higher at discharge.

    Time frame: Baseline to discharge

  14. Number of Participants With Shifts in Reference to Normal Range For Clinical Chemistry at Discharge

    For biochemistry, blood samples (10.0mL) were taken at screening, admission (if greater than 14 days since screening) and discharge/early termination. The following parameters were assessed: sodium, potassium, calcium, blood urea nitrogen (BUN)/Urea, creatinine, albumin, total protein and albumin/globulin (A/G) ratio, globulin, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), total bilirubin, glucose, chloride, and creatine kinase. A shift in reference to normal was either lower or higher at discharge.

    Time frame: Baseline to discharge

  15. Number of Participants With Shifts in Reference to Normal Range For Urinalysis at Discharge

    For urinalysis, samples were taken at screening, study admission (if greater than 14 days since screening) and discharge/early termination): glucose, blood, protein, pH, specific gravity, leukocyte esterase, and microscopic examination. A shift in reference to normal was higher at discharge.

    Time frame: Baseline to discharge

07

Results

Posted May 21, 2015

Participant flow

Treatment Period 1 (1 Day)
Participant flow — Treatment Period 1 (1 Day)
MilestoneMidodrine/PlaceboPlacebo/Midodrine
Started1311
Completed1311
Not completed00
Washout (1 Day)
Participant flow — Washout (1 Day)
MilestoneMidodrine/PlaceboPlacebo/Midodrine
Started1311
Completed1311
Not completed00
Treatment Period 2 (1 Day)
Participant flow — Treatment Period 2 (1 Day)
MilestoneMidodrine/PlaceboPlacebo/Midodrine
Started1311
Completed1311
Not completed00

Outcome measures

PrimaryTime to Onset of Near-syncopal Symptoms During Tilt Table Testing

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
1 hour post-dose
Reported as:
Mean · seconds
Time to Onset of Near-syncopal Symptoms During Tilt Table Testing
secondsMidodrine HClPlacebo
Time to Onset of Near-syncopal Symptoms During Tilt Table Testing551.3 ± 115.63461.0 ± 190.74
Statistical analysis
  • Midodrine HCl vs Placebo · Sign test · p = 0.1460 · Sign statistic: 3.0Sign test was performed per analysis plan.
SecondaryTime to Onset of Near-syncopal Symptoms in The Per-protocol Population

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
1 hour post-dose
Reported as:
Mean · seconds
Time to Onset of Near-syncopal Symptoms in The Per-protocol Population
secondsMidodrine HClPlacebo
Time to Onset of Near-syncopal Symptoms in The Per-protocol Population544.3 ± 122.34447.9 ± 199.31
Statistical analysis
  • Midodrine HCl vs Placebo · Sign test · p = 0.2266 · Sign statistic: 2.5Sign test was performed per analysis plan.
SecondaryTime to Onset of Near-syncopal Symptoms in The Per-protocol Population Analysis #2

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near- syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out. In this outcome measure, the data analyzed are the same as for Outcome Measure 4 but the summary data are presented as least squares mean (standard error).

Time frame:
1 hour post-dose
Reported as:
Least squares mean · seconds
Time to Onset of Near-syncopal Symptoms in The Per-protocol Population Analysis #2
secondsMidodrine HClPlacebo
Time to Onset of Near-syncopal Symptoms in The Per-protocol Population Analysis #2545.1 ± 36.90447.2 ± 36.90
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.0418 (The P-value is based on type III sum of squares for treatment group from a mixed effect ANOVA model with sequence, period and treatment as fixed effects, and subject within sequence as a random effect) · Least squares mean: 97.9Least squares mean for treatment difference (Midodrine HCL-Placebo)
SecondaryTime to Near-syncopal Symptoms at Treatment Visit 1

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
1 hour post-dose
Reported as:
Least squares mean · seconds
Time to Near-syncopal Symptoms at Treatment Visit 1
secondsMidodrine HClPlacebo
Time to Near-syncopal Symptoms at Treatment Visit 1539.5 ± 45.91448.4 ± 49.91
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.1928 (The P-value is based on type III sum of squares for treatment group from a one-way ANOVA model) · Least squares mean: 91.1Least squares mean for treatment difference (Midodrine HCL-Placebo)
SecondaryDuration of The Effect of Treatment at 3 Hours Post-dose

Duration of effect was defined as the difference in time to onset of near-syncopal symptoms between the first and second tilt table test, conducted at 1 hour and 3 hours post-dose, respectively, at Treatment Visit 2 (time to onset at 3 hours minus time at 1 hour). The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
1 and 3 hours post-dose
Reported as:
Mean · seconds
Duration of The Effect of Treatment at 3 Hours Post-dose
secondsMidodrine HClPlacebo
Duration of The Effect of Treatment at 3 Hours Post-dose45.1 ± 94.0348.0 ± 114.96
Statistical analysis
  • Midodrine HCl vs Placebo · t-test, 2 sided · p = 0.9479 (The P-value is from a 2-sample t-test for difference in mean)
SecondaryTotal Score of the Orthostatic Hypotension Symptom Assessment (OHSA)

The OHSA measures the severity of six symptoms/symptom complexes associated with orthostatic hypotension. Subjects rated symptoms experienced during the tilt table test on an eleven-point scale from "none" to "worst possible". The OHSA total score is the sum of six subscales, ranging from 0 (no symptoms) to 60 (worst possible symptoms). The OHSA was completed after the tilt table test was over, but was answered with reference to symptoms experienced during testing. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
Approximately 1 hour post-dose
Reported as:
Least squares mean · scores on a scale
Total Score of the Orthostatic Hypotension Symptom Assessment (OHSA)
scores on a scaleMidodrine HClPlacebo
Total Score of the Orthostatic Hypotension Symptom Assessment (OHSA)13.7 ± 2.9519.4 ± 2.95
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.0590 (The P-value is based on type III sum of squares for treatment group from a mixed effect ANOVA model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.) · Least squares mean: -5.7Least squares mean for treatment difference (Midodrine HCl - Placebo)
SecondaryScores for 6 Items of The OHSA

The OHSA measures the severity of six symptoms/symptom complexes associated with OH: dizziness, lightheadedness, and feeling faint; problems with vision; weakness; fatigue; trouble concentrating; and head/neck discomfort. Subjects rated symptoms experienced during the tilt table test on an eleven-point scale from "none" to "worst possible". Scores for each subscale range from 0 (no symptoms) to 10 (worst possible symptoms). The OHSA was completed after the tilt table test was over, but was answered with reference to symptoms experienced during testing. The tilt table test is a 10-minute assessment performed using a tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured with straps to prevent injury. After an equilibration period with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, and feeling faint.

Time frame:
Approximately 1 hour post-dose
Reported as:
Mean · scores on a scale
Scores for 6 Items of The OHSA
scores on a scaleMidodrine HClPlacebo
Dizziness, Lightheadedness, and Feeling Faint3.4 ± 3.444.7 ± 3.57
Problems with Vision1.5 ± 2.322.7 ± 3.43
Weakness3.0 ± 3.134.1 ± 3.17
Fatigue2.7 ± 3.223.5 ± 3.48
Trouble Concentrating1.7 ± 2.042.6 ± 3.13
Head/Neck Discomfort1.9 ± 2.522.1 ± 3.21
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.0633 (The P-value is based on type III sum of squares for treatment group from a mixed effect ANOVA model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.0191 (The P-value is based on type III sum of squares for treatment group from a mixed effect ANOVA model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.0727 (The P-value is based on type III sum of squares for treatment group from a mixed effect ANOVA model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.2820 (The P-value is based on type III sum of squares for treatment group from a mixed effect ANOVA model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.0880 (The P-value is based on type III sum of squares for treatment group from a mixed effect ANOVA model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.6439 (The P-value is based on type III sum of squares for treatment group from a mixed effect ANOVA model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.)
SecondaryNumber of Participants With Improvement of Clinician Clinician's Global Impression- Improvement (CGI-I) Scores After Tilt Table Test

The CGI-I instrument assesses the overall impression of the subject's orthostatic hypotension during the tilt table test by using a 7-point scale, with 1 being Very much improved; 2, Much improved; 3, Slightly improved; 4, No change; 5, Slightly worse; 6, Much worse; and 7, Very much worse. The clinician completed the CGI-I after each of the tilt table tests. A patient was assessed as "Improved" if the score was 1, 2, or 3. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
1 and 3 hours post-dose
Reported as:
Number · participants
Number of Participants With Improvement of Clinician Clinician's Global Impression- Improvement (CGI-I) Scores After Tilt Table Test
participantsMidodrine HClPlacebo
Treatment Visit 1- 1 hour post-dose, n=13, 1144
Treatment Visit 2- 1 hour post-dose, n=11, 1364
Treatment Visit 2- 3 hour post-dose, n= 11, 1235
SecondaryNumber of Participants With Improvement of Patient CGI-I Scores After Tilt Table Test

The CGI-I instrument assesses the overall impression of the subject's orthostatic hypotension during the tilt table test by using a 7-point scale, with 1 being Very much improved; 2, Much improved; 3, Slightly improved; 4, No change; 5, Slightly worse; 6, Much worse; and 7, Very much worse. The patient completed the CGI-I after each of the tilt table tests. A patient was assessed as "Improved" if the score was 1, 2, or 3. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
1 and 3 hours post-dose
Reported as:
Number · participants
Number of Participants With Improvement of Patient CGI-I Scores After Tilt Table Test
participantsMidodrine HClPlacebo
Treatment Visit 1-1 hour post-dose, n= 13, 1132
Treatment Visit 2-1 hour post-dose, n= 11, 1353
Treatment Visit 2-3 hour post-dose, n= 11, 1233
SecondaryFinal Blood Pressure During Tilt Table Testing

Blood pressure was recorded just before tilt table testing and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
1 hour post-dose
Reported as:
Mean · mmHg
Final Blood Pressure During Tilt Table Testing
mmHgMidodrine HClPlacebo
Systolic Pressure106.5 ± 37.2790.2 ± 24.17
Diastolic Pressure70.6 ± 16.4460.6 ± 15.04
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.0378 (The P-value is based on type III sum of squares for treatment group from a mixed effect ANOVA model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.0108
SecondarySystolic Blood Pressure at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2

Blood pressure was recorded just before tilt table testing, at each minute during tilt table testing, and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
1 and 3 hours post-dose
Reported as:
Mean · mmHg
Systolic Blood Pressure at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2
mmHgMidodrine HClPlacebo
At 1 minute 1 hour post-dose, n= 11, 13142.2 ± 44.2097.3 ± 24.55
At 1 minute 3 hours post-dose, n= 11, 12110.1 ± 19.0694.9 ± 31.36
At 10 minutes 1 hour post-dose, n= 10, 8121.7 ± 37.57102.9 ± 21.03
At 10 minutes 3 hours post-dose, n= 7, 6108.3 ± 30.48107.2 ± 19.32
PrimaryTime to Onset of Near-syncopal Symptoms During Tilt Table Testing Analysis #2

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near- syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out. In this outcome measure, the data analyzed are the same as for Outcome Measure 1 but the summary data are presented as least squares mean (standard error).

Time frame:
1 hour post-dose
Reported as:
Least squares mean · seconds
Time to Onset of Near-syncopal Symptoms During Tilt Table Testing Analysis #2
secondsMidodrine HClPlacebo
Time to Onset of Near-syncopal Symptoms During Tilt Table Testing Analysis #2552.4 ± 32.93460.0 ± 32.93
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.0296 (The P-value is based on type III sum of squares for treatment group from a mixed effect ANOVA model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.) · Least squares mean: 92.4Least squares mean for treatment difference (Midodrine HCl - Placebo)
SecondaryDiastolic Blood Pressure at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2

Blood pressure was recorded just before tilt table testing, at each minute during tilt table testing, and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
1 and 3 hours post-dose
Reported as:
Mean · mmHg
Diastolic Blood Pressure at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2
mmHgMidodrine HClPlacebo
At 1 minute 1 hour post-dose, n= 11, 1281.5 ± 19.0960.8 ± 13.99
At 10 minutes 1 hour post-dose, n= 10, 879.6 ± 16.1864.9 ± 11.22
At 1 minute 3 hours post-dose, n= 11, 1266.1 ± 9.6660.3 ± 18.53
At 10 minutes 3 hours post-dose, n= 7, 669.3 ± 13.5560.7 ± 14.69
SecondaryHeart Rate at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2

Heart rate was recorded just before tilt table testing, at each minute during tilt table testing, and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Time frame:
1 and 3 hours post-dose
Reported as:
Mean · beats per minute
Heart Rate at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2
beats per minuteMidodrine HClPlacebo
At 1 minute 1 hour post-dose, n= 11, 1377.6 ± 13.9380.5 ± 14.07
At 10 minutes 1 hour post-dose, n= 10, 877.7 ± 16.0879.5 ± 16.48
At 1 minute 3 hours post-dose, n= 11, 1279.7 ± 11.3080.9 ± 13.19
At 10 minutes 3 hours post-dose, n= 8, 680.9 ± 11.6681.3 ± 20.16
SecondaryNumber of Participants With Shifts in Reference to Normal Range For Hematology Analytes at Discharge

For hematology, blood samples (5.0mL) were taken at screening, study admission (if greater than 14 days since screening) and discharge/early termination. The following parameters were assessed: hemoglobin, hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cell count - total and differential (WBC), and platelet count. A shift in reference to normal was either lower or higher at discharge.

Time frame:
Baseline to discharge
Reported as:
Number · participants
Number of Participants With Shifts in Reference to Normal Range For Hematology Analytes at Discharge
participantsAll Participants
Hemoglobin1
Hematocrit0
RBC0
MCV0
MCH0
MCHC2
WBC1
Platelet count0
SecondaryNumber of Participants With Shifts in Reference to Normal Range For Clinical Chemistry at Discharge

For biochemistry, blood samples (10.0mL) were taken at screening, admission (if greater than 14 days since screening) and discharge/early termination. The following parameters were assessed: sodium, potassium, calcium, blood urea nitrogen (BUN)/Urea, creatinine, albumin, total protein and albumin/globulin (A/G) ratio, globulin, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), total bilirubin, glucose, chloride, and creatine kinase. A shift in reference to normal was either lower or higher at discharge.

Time frame:
Baseline to discharge
Reported as:
Number · participants
Number of Participants With Shifts in Reference to Normal Range For Clinical Chemistry at Discharge
participantsAll Participants
Sodium0
Potassium2
Calcium1
BUN/Urea0
Creatinine1
Albumin0
Total protein and A/G ratio2
Globulin0
ALT0
AST0
ALP1
GGT0
Total bilirubin1
Glucose6
Chloride0
Creatine kinase1
PrimaryTime to Onset of Near-syncopal Symptoms During Tilt Table Testing-Re-analysis With The Koch Procedure

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out. The Koch procedure is a 3-step process to analyze results while utilizing the available information on magnitude of differences.

Time frame:
1 hour post-dose
Reported as:
Mean · seconds
Time to Onset of Near-syncopal Symptoms During Tilt Table Testing-Re-analysis With The Koch Procedure
secondsMidodrine HClPlacebo
Time to Onset of Near-syncopal Symptoms During Tilt Table Testing-Re-analysis With The Koch Procedure551.3 ± 115.63461.0 ± 190.74
Statistical analysis
  • Midodrine HCl vs Placebo · Signed Rank Test · p = 0.0342
SecondaryNumber of Participants With Shifts in Reference to Normal Range For Urinalysis at Discharge

For urinalysis, samples were taken at screening, study admission (if greater than 14 days since screening) and discharge/early termination): glucose, blood, protein, pH, specific gravity, leukocyte esterase, and microscopic examination. A shift in reference to normal was higher at discharge.

Time frame:
Baseline to discharge
Reported as:
Number · participants
Number of Participants With Shifts in Reference to Normal Range For Urinalysis at Discharge
participantsAll Participants
Glucose1
Blood2
Protein0
pH0
Specific gravity0
Leukocyte esterase2
Microscopic examination0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Midodrine/Placebo—1/13 (7.7%)3/13 (23.1%)
Placebo/Midodrine—0/11 (0%)2/11 (18.2%)
Most frequent serious events
Most frequent serious events
EventMidodrine/PlaceboPlacebo/Midodrine
Multiple sclerosis aggravatedNervous system disorders1/130/11
Most frequent other events
Most frequent other events
EventMidodrine/PlaceboPlacebo/Midodrine
Hypertension aggravatedVascular disorders0/132/11
NauseaGastrointestinal disorders1/130/11
Atrioventricular block first degreeCardiac disorders1/130/11
Vomiting NOSGastrointestinal disorders1/130/11
HypokalaemiaMetabolism and nutrition disorders1/130/11
DizzinessNervous system disorders1/130/11
Headache NOSNervous system disorders1/130/11

Baseline characteristics

The Safety and Full Analysis Set (FAS) populations, defined as all participants who received at least one dose of investigational product (Safety) and all participants who were randomized, received at least one dose of investigational product, and had at least one measurement of the time to near syncope during a tilt table test (FAS).

Age, Continuous
Age, Continuous(years)Midodrine/PlaceboPlacebo/MidodrineTotal
Mean59.4 ± 17.8460.8 ± 12.9160.0 ± 15.46
Sex: Female, Male
Sex: Female, Male(Participants)Midodrine/PlaceboPlacebo/MidodrineTotal
Female7512
Male6612
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Midodrine/PlaceboPlacebo/MidodrineTotal
Hispanic or Latino000
Not Hispanic or Latino131124
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Midodrine/PlaceboPlacebo/MidodrineTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American213
White111021
More than one race000
Unknown or Not Reported000
08

Study locations

11 sites
  • Fort Wayne Neurological Center
    Fort Wayne, Indiana 46805, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Minnesota VA Medical Center
    Minneapolis, Minnesota 55417, United States
  • Forest Park Neurophysiology
    Saint Louis, Missouri 63139, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Absher Neurology, PA
    Greenville, South Carolina 29615, United States
  • Vanderbilt University
    Nashville, Tennessee 37212, United States
  • Diabetes and Glandular Disease research Associates, PA
    San Antonio, Texas 78229, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2004 to primary completion in Mar 2005, 6 months.

Results were first posted in May 2015, 10 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2007
First posted
Nov 9, 2007
StartActual
Sep 8, 2004
Primary completionActual
Mar 21, 2005
CompletionActual
Mar 21, 2005
Results first posted
May 21, 2015
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00555880
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Nov 9, 2007
Start date
Sep 8, 2004
Primary completion
Mar 21, 2005
Completion
Mar 21, 2005
Results posted
May 21, 2015
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midodrine

Start the discussion